Letter to Secretary Burwell Re: Long-Term Care Pharmacy
The Senior Care Pharmacy Coalition (“SCPC”), on behalf of the long term care (“LTC”) pharmacies it represents and the residents of LTC facilities whom those pharmacies serve, is writing to ask your help in reconciling a conflict between two of the agencies within your Department – the Food and Drug Administration (“FDA”) and the Center for Medicare and Medicaid Services (“CMS”) – related to packaging of prescription drugs in long term care (“LTC”) pharmacies. The CMS Requirements of Participation for nursing homes require LTC pharmacies to dispense medications to residents in specialized packaging and provide emergency medications that must be kept on-site at the facility (known as “e-kits”). However a draft FDA guidance issued in 2015 entitled “Draft Guidance for Industry: Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities” (Feb. 2015) (the “Draft Guidance”) would, if finalized, prohibit LTC pharmacies for preparing the very same packaging and providing e-kits for residents of LTC facilities that the Requirements of Participation demand. The vast majority of medications dispensed for these patients are not available from manufacturers, wholesalers or licensed repackagers in the appropriate specialized packaging. Given that LTC pharmacies have for decades been safely packaging these medications in compliance with CMS and pharmacy requirements, we seek your assistance to avoid the emerging conflict.
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.